The evaluation of adiponectin gene polymorphisms (rs2241766 and rs1501299) in susceptibility to severe coronary artery disease in a north Iranian population.

Abstract

BackgroundSeveral genome-wide-association-studies have approved a series of adiponectin polymorphisms firmly associated with coronary artery disease (CAD), type 2 diabetes mellitus and related metabolic traits. In this study, the relationship between +45 T/G (rs2241766) and the +276 G/T(rs1501299) adiponectin polymorphisms was investigated with coronary heart disease, antioxidant capacity, and plasma lipid profiles in diabetic and non-diabetic subjects. MethodsIn this cross-sectional study, 274 blood samples were collected from 131 male and 143 female Iranian volunteers suspected of coronary heart disease based on angiographic evidence.PCR-RFLP method was used to determine the adiponectin genotypes in two variants, +45 T/G (rs2241766) and + 276 G/T(rs1501299). Total antioxidant capacity (TAC) was estimated through the Ferric Reducing Ability of Plasma (FRAP), and also, the Elman method was applied to evaluate total thiol. Plasma lipid profiles and FBS were measured by spectrophotometric methods. ResultsComparison of clinical and demographic factors in the two groups of CAD+ and non-CAD showed a significant differences between age, triglyceride, insulin and FRAP levels (P < 0.05). there was no significant variation in the probability of developing coronary artery disease or diabetes mellitus due to genotypic and allelic frequencies at the two gene polymorphism +45 T/G(rs2241766) and + 276 G/T(rs1501299). Data analysis explained that adiponectin +45 T/G variants correlated with plasma lipid profile and glycemic index in diabetic subjects. However, this relationship was not observed for the +276 G/T variant. ConclusionThe results showed that the adiponectin gene polymorphism (45 T/G, +276G/T) had not significantly correlation with coronary artery disease in most variants and only the GG variant of 45 T/G can develop the risk of coronary artery disease in male individuals with diabetes.